

*PHYSIOLOGICALLY
BASED
PHARMACOKINETIC
MODELING*

PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING

Science and Applications

EDITED BY

MICAELA B. REDDY, PH.D.

*Colorado State University
Fort Collins, Colorado*

RAYMOND S. H. YANG, PH.D.

*Colorado State University
Fort Collins, Colorado*

HARVEY J. CLEWELL III, M.A.

*CIIT Centers for Health Research
Research Triangle Park, North Carolina*

MELVIN E. ANDERSEN, PH.D.

*CIIT Centers for Health Research
Research Triangle Park, North Carolina*

 **WILEY-
INTERSCIENCE**

A JOHN WILEY & SONS, INC., PUBLICATION

Copyright © 2005 by John Wiley & Sons, Inc. All rights reserved.

Published by John Wiley & Sons, Inc., Hoboken, New Jersey.

Published simultaneously in Canada.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400, fax 978-646-8600, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008.

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services please contact our Customer Care Department within the U.S. at 877-762-2974, outside the U.S. at 317-572-3993 or fax 317-572-4002.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print, however, may not be available in electronic format.

Library of Congress Cataloging-in-Publication Data:

Physiologically based pharmacokinetic modeling : science and application / edited by Micaela B. Reddy . . . [et al.].

p. cm.

Includes index.

ISBN 0-471-47814-8 (cloth)

1. Pharmacokinetics. 2. Xenobiotics. 3. Toxicology. I. Reddy, Micaela B. RM301.5.P53 2005 615'.7—dc22

2005005177

Printed in the United States of America

10 9 8 7 6 5 4 3 2 1

CONTENTS

<i>PREFACE</i>	xiii
<i>ACKNOWLEDGMENTS</i>	xv
<i>CONTRIBUTORS</i>	xvii
CHAPTER 1 <i>INTRODUCTION: A HISTORICAL PERSPECTIVE OF THE DEVELOPMENT AND APPLICATIONS OF PBPK MODELS</i>	1
1.1 Introduction	1
1.2 A Historical Perspective	2
1.2.1 Responses to Inhaled Compounds	3
1.2.2 Pharmaceutical Applications	3
1.2.3 Occupational and Environmental Applications	4
1.2.4 Digital Computation and PBPK Modeling	5
1.3 Expansion of PBPK Model Applications	6
1.3.1 PBPK Models for Tissue Dosimetry from Secondary Data	7
1.3.2 Biological Mechanisms Underlying Pharmacokinetic Behaviors	8
1.3.3 Chemicals as Probes of Biological Processes	9
1.3.4 Risk Assessment Applications	10
1.3.5 PBPK Models as Repository of Mechanistic Data on Distribution and Response	12
1.4 Summary	13
Notation	14
References	15

PART I *PBPK MODELING FOR VOLATILE ORGANIC COMPOUNDS*

CHAPTER 2 <i>HALOGENATED ALKANES</i>	21
2.1 Introduction	21
2.2 PBPK Model Development for Volatile Organics	21
2.2.1 Model Formulation	22
2.2.2 Model Equations	23
2.2.3 Model Parameterization	25
2.2.4 Model Calculations	26
2.3 Experimental Methods Demonstrated for Groups of Chemicals	26
2.4 PBPK Models for Halogenated Alkanes	29
2.4.1 Anesthetic Gases	29

2.4.2	Chlorofluorocarbons (CFCs), Refrigerants, and Halons	31
2.4.3	Halogenated Alkanes	34
2.5	Summary	47
	Notation	47
	References	49

CHAPTER 3 HALOGENATED ALKENES

55

3.1	Introduction	55
3.2	The Chloroethylenes: Background	56
3.3	Review of PBPK Models	59
3.3.1	Vinyl Chloride (VC)	59
3.3.2	Vinyl Fluoride (VF)	61
3.3.3	<i>cis</i> -1,2-Dichloroethylene (cDCE) and <i>trans</i> -1,2-Dichloroethylene (tDCE)	62
3.3.4	Vinylidene Chloride (VDC)	63
3.3.5	Trichloroethylene (TCE)	64
3.3.6	Tetrachloroethylene (PERC)	69
3.3.7	Allyl Chloride (AC)	72
3.3.8	β -Chloroprene (CD)	73
3.3.9	Hexachlorobutadiene, HCB	73
3.4	Summary	74
	Notation	74
	References	75

CHAPTER 4 ALKENE AND AROMATIC COMPOUNDS

79

4.1	Introduction	79
4.2	PK and Pharmacodynamic Properties Important in PBPK Model Development for Aromatic and Alkene Compounds	81
4.2.1	Metabolism and Mode of Action	81
4.2.2	Model Structures	82
4.2.3	PK Differences	83
4.2.4	Extrahepatic Metabolism and Transport of Metabolites	83
4.2.5	GSH Conjugation	83
4.2.6	Endogenous Production	84
4.2.7	Reactivity with DNA and Protein	84
4.2.8	Inhibition of Second Oxidative Steps	84
4.2.9	Variability and PK Differences	84
4.2.10	Subcompartments in PBPK Models	85
4.2.11	“Privileged Access” of Epoxide Hydratase to Epoxide Substrates	85
4.3	Review of Aromatic and Alkene PBPK Models	85
4.3.1	Benzene—A Known Human Carcinogen with an Uncertain Mode of Action	85
4.3.2	Styrene—Early PBPK Models	90
4.3.3	1,3-Butadiene	96
4.3.4	Isoprene	101
4.3.5	Ethylene, Propylene, and Their Oxides	102
4.3.6	Naphthalene and Other PAHs	103
4.3.7	Halobenzenes	105
4.3.8	Miscellaneous Related Compounds	108

4.4	Summary	110
	Notation	110
	References	111

CHAPTER 5 *REACTIVE VAPORS IN THE NASAL CAVITY*
119

5.1	Introduction	119
5.1.1	Nasal Effects and Risk Assessment	119
5.1.2	General Models for Nasal Uptake	120
5.2	No Air-Phase Models	122
5.2.1	The “Perfused Nose” Model	122
5.2.2	Vinyl Acetate	124
5.3	Creating the Air-Phase Compartments	126
5.3.1	Computational Fluid Dynamics	126
5.3.2	Estimating the Air-Phase Mass Transfer Coefficient	126
5.3.3	Estimating Air-Phase Mass Transfer Coefficients—Acrylic Acid	127
5.4	Other Models for Vapors Affecting Nasal Tissues	128
5.4.1	Vinyl Acetate	128
5.4.2	Ethyl Acrylate and Its Metabolite, Acrylic Acid	128
5.4.3	Epichlorohydrin	131
5.5	Methyl Methacrylate	132
5.6	Formaldehyde	134
5.7	Hydrogen Sulfide	137
5.8	Summary	137
	Notation	138
	References	138

CHAPTER 6 *ALKANES, OXYHYDROCARBONS, AND RELATED COMPOUNDS*
141

6.1	Introduction	141
6.2	Purposes for PBPK Model Development	142
6.3	PBPK Models for Four Classes of Compounds	143
6.3.1	Alkanes	143
6.3.2	Oxyhydrocarbons	145
6.3.3	Alkylbenzenes	155
6.3.4	Siloxanes	160
6.4	Summary	162
	Notation	162
	References	163

PART II *PBPK MODEL DEVELOPMENT FOR ENVIRONMENTAL POLLUTANTS*

CHAPTER 7 *PESTICIDES AND PERSISTENT ORGANIC POLLUTANTS (POPs)*
169

7.1	Introduction	169
7.2	Pesticides	172
7.2.1	Chemical Classes of Pesticides	172
7.2.2	Modeling Tissue Distribution	174

7.2.3	Modeling Metabolism	180
7.2.4	Summary of Individual Models	182
7.3	Polychlorinated and Polybrominated Biphenyls (PCBs and PBBs)	193
7.3.1	Modeling in Mammals	194
7.3.2	Modeling in Nonmammalian Species	197
7.4	Summary	197
	Notation	198
	References	198

CHAPTER 8 DIOXIN AND RELATED COMPOUNDS

207

8.1	Introduction	207
8.2	Toxicity	208
8.3	Mode of Action	210
8.4	Pharmacokinetics	211
8.4.1	Absorption, Metabolism, and Excretion	212
8.4.2	Distribution	212
8.5	PBPK Models of TCDD	213
8.5.1	PBPK Models of TCDD in Rodents	214
8.5.2	PBPK Models of TCDD in Humans	226
8.6	Summary	228
	Notation	228
	References	229

CHAPTER 9 METALS AND INORGANIC COMPOUNDS

239

9.1	Introduction	239
9.2	Physiologically Based Modeling of Metals	240
9.2.1	Arsenic	243
9.2.2	Nickel	246
9.2.3	Lead	248
9.2.4	Chromium	255
9.3	PBPK Models for Nonmetals	258
9.3.1	A PBPK Model for Fluoride, a Bone-Seeking Nonmetal	258
9.3.2	PBPK Models for Other Nonmetals	259
9.4	Compartmental Models for Miscellaneous Inorganic and/or Endogenous Chemicals	260
9.5	Research Needs	260
9.5.1	The Need for Physiologically Based Modeling for Essential Metals	260
9.5.2	Other Research Needs	261
9.6	Summary	263
	Notation	263
	References	264

PART III PHARMACEUTICAL APPLICATIONS OF PBPK MODELS

CHAPTER 10 DRUGS

273

10.1	Introduction	273
10.2	Describing the Tissue Distribution of Drugs	274

10.3	Describing Metabolism and Other Clearance Processes of Drugs	281
10.4	Other Issues in Model Development for Drugs	284
10.4.1	Altered Physiological States	284
10.4.2	Drug Stereospecificity	286
10.4.3	Non-Steady-State Dynamics	286
10.4.4	Drug Interactions	287
10.4.5	Utilization of <i>In Vitro</i> Data	290
10.5	Future Perspectives	292
10.6	Summary	292
	Notation	293
	References	293

CHAPTER 11 ANTINEOPLASTIC AGENTS

297

11.1	Introduction	297
11.2	PBPK Models for Antineoplastic Agents	298
11.2.1	Methotrexate	298
11.2.2	<i>cis</i> -Dichlorodiammine-platinum	302
11.2.3	Actinomycin D	305
11.2.4	2'-Deoxycoformycin (Pentostatin)	306
11.2.5	5-Fluorouracil	307
11.2.6	2-Amino-1,3,4-thiadiazole	309
11.2.7	1- β -D-Arabinofuranosylcytosine	309
11.2.8	Adriamycin	310
11.2.9	Melphalan	312
11.2.10	Topotecan	313
11.2.11	17-(Allylamino)-17-demethoxygeldanamycin	314
11.3	Summary	315
	Notation	315
	References	316

PART IV PBPK MODELING APPROACHES FOR SPECIAL APPLICATIONS

CHAPTER 12 PERINATAL PHARMACOKINETICS

321

12.1	Introduction	321
12.2	Physiological and Biochemical Changes During Pregnancy	323
12.2.1	Body Weight Changes and Organ Growth	323
12.2.2	Physiological and Biochemical Changes in Pregnant Females	323
12.2.3	Physiological Changes in Fetuses	326
12.2.4	Mechanisms of Chemical Transfer Through Placenta	326
12.2.5	Mechanisms of Chemical Transfer Through Breast Milk	327
12.3	Physiological Factors Incorporated into PBPK Models for Perinatal Pharmacokinetics	328
12.3.1	Body Weight in the Mother	329
12.3.2	Organ Volume and Cardiac Output in the Mother	329
12.3.3	Chemical Transfer Through the Placenta and Mammary Gland	331
12.3.4	Body Weight and Organ Volume in the Fetus/Pup	331

X CONTENTS

12.4	PBPK Models for Perinatal Transfer	333
12.4.1	Tetracycline	333
12.4.2	Morphine	333
12.4.3	Theophylline	334
12.4.4	Methadone	334
12.4.5	Pethidine	334
12.4.6	Trichloroethylene	335
12.4.7	5,5'-Dimethyloxazolidine-2,4-Dione (DMO)	335
12.4.8	Tetrachloroethylene	335
12.4.9	2-Methoxyethanol and Methoxyacetic Acid	336
12.4.10	Methylmercury (MeHg)	338
12.4.11	2,4-Dichlorophenoxyacetic Acid (2,4-D)	338
12.4.12	Methanol	339
12.4.13	Vitamin A Acid	339
12.4.14	Organic Solvents	339
12.4.15	<i>p</i> -Phenylbenzoic Acid (PPBA)	340
12.4.16	<i>p,p'</i> -Dichloro-2,2- <i>bis</i> (<i>p</i> -chlorophenyl)ethylene (DDE)	340
12.4.17	2-Ethoxyethanol and Ethoxyacetic Acid	340
12.4.18	Perchlorate	341
12.5	Risk Assessment Dosimetry Models	342
12.6	Summary	342
	Notation	343
	References	344

CHAPTER 13 MIXTURES

349

13.1	Introduction	349
13.2	PBPK Modeling of Chemical Mixtures	350
13.2.1	Earlier Days: PBPK Modeling of Binary Mixtures	350
13.2.2	More Recent Endeavor: PBPK Modeling of Higher-Order Mixtures	362
13.3	Future Perspectives: Second-Generation PBPK/PD Modeling	367
13.4	Summary	368
	Notation	369
	References	370

CHAPTER 14 DERMAL EXPOSURE MODELS

375

14.1	Introduction	375
14.2	Factors to Consider in Modeling Dermal Absorption	376
14.3	Dermal Absorption Models	378
14.3.1	Membrane Models	378
14.3.2	Compartment Models	379
14.4	Experimental Methods	383
14.5	Summary	384
	Notation	385
	References	385

CHAPTER 15 CONCLUSIONS AND FUTURE DIRECTIONS

389

15.1	Introduction	389
15.2	A Systems Approach for Pharmacokinetics	390

15.3	Modeling Both Dose and Response	391
15.4	Opportunities for PBPK Modeling in the Pharmaceutical Industry	392
15.5	Reaction Network Modeling with Xenobiotics	393
15.6	Systems Biology and Dose–Response	394
15.7	Summary	397
	Notation	397
	References	397

PREFACE

In recent years, there has been an enormous expansion of uses of physiologically based pharmacokinetic (PBPK) modeling in areas related to environmental chemicals and drugs. For individuals interested in PBPK modeling, it is relatively easy to locate and use the contributions of previous authors on a specific chemical of interest. However, it is more difficult to locate broader sets of contributions containing useful modeling techniques and applications. Our purpose was to provide a broad review of the PBPK modeling literature, before the size of the body of work grew large enough to make such an effort prohibitive, and to provide a resource to contain comprehensive coverage of the PBPK modeling literature from its beginnings in the mid-1900s through the first few years of the twenty-first century. This monograph is meant to be a useful reference and educational tool for those professionals and graduate students in toxicology, pharmacology, computational biology, and risk assessment interested in PBPK modeling as a tool for quantifying tissue doses and for describing the response of organisms to chemical exposures.

Our initial literature search in 2001 and updated in 2002, conducted using the Web of Science, Medline, and Toxline databases and incorporating keywords such as physiologically based pharmacokinetic/PBPK model, physiologically based toxicokinetic/PBTK model, and physiologically based pharmacodynamic/PBPD model, uncovered over 1000 references. As the term PBPK model did not become popular until the 1980s, for earlier contributions we relied on literature searches using the names of authors known by the editors to have made early contributions in the field, followed up by searches on other authors and articles cited in these articles. We chose to organize this diverse body of work based on classes of chemicals (e.g., volatile organics and environmental contaminants) and modeling purposes (e.g., perinatal transfer models and dermal absorption models). Our goal was to be fairly comprehensive, but to stress primary contributions in PBPK model development and in applications of these models to investigate factors that regulate chemical distribution within the body. We have also attempted to include articles that appeared over the past few years during completion of this volume. While we have made attempts to be inclusive in our coverage of the PBPK modeling literature, some important contributions may have been missed in our review process. We apologize to authors whose work may have been inadvertently overlooked in these various chapters and not captured by the editorial review.

This monograph describes the development of PBPK modeling for toxic compounds over the past eight decades and their current uses, providing background on the basics of PBPK modeling for understanding the physical, chemical, and biological properties that determine absorption, distribution, metabolism, and elimination of xenobiotics. Early PBPK modeling applications with volatile anesthetics and

chemotherapeutics paved the way for applying these techniques to a wide range of volatile compounds of occupational and environmental significance. The past 15 years have witnessed extensive application with many other classes of chemicals: metals, inorganic chemicals, pesticides, persistent organics pollutants, drugs, and the metabolites of these classes of chemicals. PBPK models have played important roles in unraveling dose–response behaviors based on estimates of tissue dose and have revolutionized low dose and interspecies extrapolations in risk assessment. Following an introductory chapter on PBPK modeling, a series of chapters reviews PBPK model results for various classes of compounds with coverage of historical development, modeling challenges specific to classes of chemicals, and current practices. Comments are also provided regarding the use of these PBPK models to support pharmacodynamic modeling for various toxic responses and future directions where modeling approaches will be helpful.

This monograph arose through efforts of graduate students, postdoctoral fellows, and professors at Colorado State University to review literature in specific areas and produce a series of chapters. These individuals worked in the Quantitative and Computational Toxicology Program at the Center for Environmental Toxicology and Technology in the Department of Environmental and Radiological Health Sciences. Many of these individuals have graduated from Colorado State and left for other positions. The editors wish to express their sincere appreciation for all the assistance provided by these individuals in developing this monograph. Each of these individuals is cited as the authors on the chapters where they contributed.

Micaela B. Reddy
Raymond S. H. Yang
Harvey J. Clewell III
Melvin E. Andersen

ACKNOWLEDGMENTS

The concepts and work discussed in this presentation were partially contributed by many colleagues associated or collaborating with the Quantitative and Computational Toxicology group at Colorado State University; we are grateful for their contributions and intellectual stimulation. Any advances in science require funding support from many agencies. We thank NIH (Superfund Basic Research Program Project P42 ES05949; research grants R01 ES09655; 3 RO1 ES-09655-01S1, and RO3 ES10116 ZES1; training grants T32 ES 07321, F32 ES 11425, and 1 F32 ES 05901; and Career Development Awards 1 K08 CA72396, 1 K01 CA75955-01A1, and 01 K25 ES11146), ATSDR (Cooperative Agreement U61/ATU881475), NIOSH/CDC (research grant 1 RO1 OH07556-01), US Air Force (research grants F33615-91-C-0538; F49620-94-1-0304), US Navy (research contract, F3360195MSA05), and USEPA (Cooperative Agreement CR 821922-01-0; Contract No. 3C-R102-NTEX). Without the generous support of these agencies, the development of some of the research described herein and the writing of this monograph could have never been possible.

Two of the authors, MEA and HJC, gratefully acknowledge support from the Long-range Research Initiative program of the American Chemistry Council (LRI-ACC) for their continuing support of development of PBPK tools to improve human health risk assessment. We also want to acknowledge our debt to colleagues from our Wright-Patterson AFB years, Drs. Michael MacNaughton, Michael Gargas, Jeff Fisher, and James McDougal, who were all critical parts of a team of scientists that initially developed the experimental methods and modeling tools to support PBPK modeling in toxicology and risk assessment.

Several individuals made important contributions in this project. We thank Dr. Ying Ou, who initiated the project. The authors also thank Mr. Roger Paxton, Miss Christina Barinque, Miss Lisa Casuto, and Mrs. Linda Monum for their valuable assistance with the monograph.

CONTRIBUTORS

Andersen, Melvin, E., Ph.D.
Division of Computational Biology
CIIT Centers for Health Research
Research Triangle Park, NC 27709-2137

Bae, Dong-Soon, Ph.D.
Laboratory of Cellular Carcinogenesis and Tumor Promotion
National Cancer Institute
National Institutes of Health
Bethesda, MD 20892-4255

Belfiore, Carol J., Ph.D.
Quantitative and Computational Toxicology Group
Center for Environmental Toxicology and Technology
Department of Environmental and Radiological Health Sciences
Colorado State University
Fort Collins, CO 80523-1690

Campaign, Julie, Ph.D.
Center for Environmental Toxicology and Technology
Department of Environmental and Radiological Health Sciences
Colorado State University
Fort Collins, CO 80523-1690

Clewell, Harvey J., III, M.A.
Center for Human Health Assessment
CIIT Centers for Health Research
Research Triangle Park, NC 27709-2137

Davidson, Robert T., Ph.D.
Department of Nutrition, Dietetics, and Food Science
Brigham Young University
Provo, UT 84602

Dennison, James E., Ph.D.
Quantitative and Computational Toxicology Group
Center for Environmental Toxicology and Technology

xviii **CONTRIBUTORS**

Department of Environmental and Radiological Health Sciences
Colorado State University
Fort Collins, CO 80523-1690

Dobrev, Ivan D., Ph.D.
Quantitative and Computational Toxicology Group
Center for Environmental Toxicology and Technology
Department of Environmental and Radiological Health Sciences
Colorado State University
Fort Collins, CO 80523-1690

Lee, Sun K., Ph.D.
Quantitative and Computational Toxicology Group
Center for Environmental Toxicology and Technology
Department of Environmental and Radiological Health Sciences
Colorado State University
Fort Collins, CO 80523-1690
Present Address:
Hoffman–LaRoche
Nonclinical Drug Safety
Nutley, NJ 07110

Lu, Yasong, M.S.
Quantitative and Computational Toxicology Group
Center for Environmental Toxicology and Technology
Department of Environmental and Radiological Health Sciences
Colorado State University
Fort Collins, CO 80523-1690

McMullin, Tami S., B.S.
Department of Environmental and Radiological Health Sciences
Colorado State University
Fort Collins, CO 80523-1690

Pott O'Brien, Wendy, D.V.M., Ph.D.
United States Environmental Protection Agency, Region 8
Denver, CO 80202

Reddy, Micaela B., Ph.D.
Quantitative and Computational Toxicology Group
Center for Environmental Toxicology and Technology
Department of Environmental and Radiological Health Sciences
Colorado State University
Fort Collins, CO 80523-1690

Yang, Raymond S. H., Ph.D.
Quantitative and Computational Toxicology Group
Center for Environmental Toxicology and Technology
Department of Environmental and Radiological Health Sciences
Colorado State University
Fort Collins, CO 80523-1690